Advances in melanoma therapy

Journal of the American Academy of Dermatology

Volumn 38, Issue 5 I, 1998, Pages 731-741

  Johnson, T M ^a   Yahanda, A M ^a   Chang, A E ^a   Fader, D J ^a   Sondak, V K ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

ANTINEOPLASTIC ACTIVITY; CANCER STAGING; CANCER SURVIVAL; IMMUNOTHERAPY; LYMPH NODE METASTASIS; LYMPHOCYTE ACTIVATION; MELANOMA; PRIORITY JOURNAL; REVIEW;

EID: 0031901128     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(98)70202-6     Document Type: Article

References (72)

1. DS Rigel Malignant melanoma: perspectives on incidence and its effect on awareness, diagnosis and treatment CA Cancer J 46 1996 195 198
2. DG Coit A Rogatko MF Brennan Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes Ann Surg 214 1991 627 636
3. Malignant melanoma of the skin (excluding eyelid) 4th ed OH Beahrs DE Henson RVP Hutter BJ Kennedy American Joint Committee on Cancer Manual for staging of cancer 1992 JB Lippincott Philadelphia 143 148
4. CM Balch N Cascinelli KT Drzewiecki J Eldh RM Mackie WH McCarthy A comparison of prognostic factors worldwide 2nd ed CM Balch AN Houghton GW Milton AJ Sober SJ Soon Cutaneous melanoma 1992 JB Lippincott Philadelphia 188 199
5. TM Johnson JW Smith BR Nelson A Chang Current therapy for cutaneous melanoma J Am Acad Dermatol 32 1995 689 707
6. DL Morton L Wanek JA Nizze RM Elashoff JH Wong Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: analysis of prognostic factors in 1134 patients from John Wayne Cancer Clinic Ann Surg 214 1991 491 499
7. MH Cohen AS Ketcham EL Felix SH Li MM Tomaszewski J Costa Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma Ann Surg 186 1977 635 642
8. C Callery AJ Cochran DJ Roe W Rees SD Nathanson JK Benedetti Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes Ann Surg 196 1982 69 75
9. A Calabro SE Singletary CM Balch Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases Arch Surg 124 1989 1051 1055
10. RG Bevilacqua DG Coit A Rogatko RN Younes MF Brennan Axillary dissection in melanoma: prognostic variables in node-positive patients Ann Surg 212 1990 125 131
11. IM Ariel Malignant melanoma of the trunk: a retrospective review of 1128 patients Cancer 49 1982 1070 1078
12. CM Balch SJ Soong GW Milton HM Shaw VJ McGovern TM Murad A comparison of prognostic factors and surgical results in 1786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia Ann Surg 196 1982 677 684
13. DS Reintgen EB Cox KS McCarthy RT Vollmer HF Seigler Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma Ann Surg 198 1983 379 385
14. CM Balch The role of elective lymph node dissection in melanoma: rationale, results, and controversies J Clin Oncol 6 1988 162 172
15. GW Milton HM Shaw WH McCarthy L Pearson CM Balch SJ Soong Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients Br J Surg 69 1982 108 111
16. U Veronesi J Adams DC Bandiera O Brennhovd E Caceres N Cascinelli Delayed regional lymph node dissection in stage I malignant melanoma of the skin of the lower extremities Cancer 49 1982 2420 2430
17. FH Sim WF Taylor DJ Pritchard EH Soule Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study Mayo Clin Proc 61 1986 697 705
18. CM Balch SJ Soong AA Bartolucci MM Urist CP Karakousis TJ Smith Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger Ann Surg 224 1996 255 266
19. JM Kirkwood MH Strawderman MS Ernstoff TJ Smith EC Borden RH Blum Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684 J Clin Oncol 14 1996 7 17
20. U Veronesi J Adamus DC Bandiera IO Brennhovd E Caceres N Cascinelli Stage I melanoma of the limbs: immediate versus delayed node dissection Tumori 66 1980 373 396
21. DL Morton DR Wen JH Wong JS Economou LA Cagle FK Storm Technical details of intraoperative lymphatic mapping for early stage melanoma Arch Surg 127 1992 392 399
22. DL Morton DR Wen LJ Foshag R Essner AJ Cochran Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early stage melanomas of the head and neck J Clin Oncol 11 1993 1751 1756
23. R Essner The role of lymphoscintigraphy and sentinel node mapping in assessing patient risk in melanoma Semin Oncol 24 1997 S4 S8 –S4-10
24. HJ Fee DS Robinson WG Sample LS Graham EC Holmes DL Morton The determination of lymph shed by colloidal gold scanning in patients with malignant melanoma: a preliminary study Surgery 84 1978 626 632
25. J Norman CW Cruse C Espinosa E Ruas E Beatty S Hymes Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma Am J Surg 162 1991 432 437
26. D Reintgen CW Cruse K Wells C Berman N Fenske F Glass The orderly progression of melanoma nodal metastases Ann Surg 6 1994 759 767
27. JC Alex DL Weaver JT Fairbank Gamma probe-guided lymph node localization in malignant melanoma Surg Oncol 2 1993 303 308
28. MI Ross Surgical management of stage I and II melanoma patients: approach to the regional lymph node basin Semin Surg Oncol 12 1996 394 401
29. MI Ross D Reintgen CM Balch Selective lymph-adenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma Semin Surg Oncol 9 1993 219 223
30. JJ Albertini CW Cruse D Rapaport K Wells M Ross R DeConti Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma Ann Surg 223 1996 217 224
31. DL Morton AM Conforti Sentinel lymphadenectomy for clinical stage I melanoma: current status Melanoma Lett 15 1997 1 4
32. J Gershenwald W Thompson P Mansfield J Lee M Colome C Balch Patterns of failure in melanoma patients after successful lymphatic mapping and negative sentinel node biopsy [abstract] The Society of Surgical Oncology 20 1996 49th Cancer Symposium
33. F Doi DDJ Chi BB Charuworn AJ Conrad J Russell DL Morton Detection of B-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma Int J Cancer 65 1996 454 459
34. X Wang R Heller N VanVoorhis CW Cruse F Glass N Fenske Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma Ann Surg 220 1994 768 774
35. KF Carson DR Wen P Li C Bailly DL Morton AJ Cochran Nodal nevi and cutaneous melanomas Am J Surg Pathol 20 1996 834 840
36. MJ Arca JS Biermann TM Johnson AE Chang Biopsy techniques for skin, soft-tissue, and bone neoplasms MC Wilhelm Surgical oncology clinics of North America 1995 WB Saunders Co Philadelphia 157 174
37. M Demierre HK Koh Adjuvant therapy for cutaneous malignant melanoma J Am Acad Dermatol 36 1997 747 764
38. DL Morton FR Eilber RA Malmgren WC Wood Immunological factors which influence response to immunotherapy in malignant melanoma Surgery 68 1970 158 164
39. VK Sondak JA Wolfe Adjuvant therapy of melanoma Curr Opin Oncol 9 1997 189 204
40. VK Sondak KJ Kopecky JW Smith II E Hersh RD Noyes RD Tuthill Is interferon-alpha detrimental? Results of a Southwest Oncology Group randomized trial of adjuvant human interferon-alpha versus observation in malignant melanoma SE Salmon Adjuvant therapy of cancer 1997 Lippincott-Raven Philadelphia 259 272
41. ET Creagan RJ Dalton DL Ahmann SH Jung RF Morton RM Langdon Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma J Clin Oncol 13 1995 2776 2783
42. BF Cole RD Gelber JM Kirkwood A Goldhirsch E Barylak E Borden A quality-of-life–adjusted survival analysis of interferon alpha-2b adjuvant treatment for high risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group Study (E1684) J Clin Oncol 14 1996 2666 2673
43. BE Hillner JM Kirkwood MB Atkins ER Johnson TJ Smith Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group study 1684 J Clin Oncol 15 1997 2351 2358
44. MW Kattan Y Inoue FJ Giles M Talpaz H Ozer F Guilhot Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia Ann Intern Med 125 1996 541 548
45. JB Wong RS Koff F Tine SG Pauker Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B antigen-positive chronic hepatitis B Ann Intern Med 122 1995 664 675
46. WG Bennett Y Inoue JR Beck SG Pauker GL Davis Justification of a single 6-month course of interferon (IFN) for histologically mild chronic hepatitis C [abstract] Hepatology 22A 1995 290
47. SA Rosenberg Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens J Natl Cancer Inst 88 1996 1635 1644
48. CL Slingluff Tumor antigens and tumor vaccines: peptides as immunogens Semin Surg Oncol 12 1996 446 453
49. JC Skipper RC Hendrickson PH Gulden V Brichard A Van Pel Y Chen An HLA-A2–restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel pathway for processing of membrane proteins J Exp Med 183 1996 527 534
50. T Wolfel A Van Pel V Brichard J Schneider B Seliger KH Meyer zum Buschenfelde Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes Eur J Immunol 24 1994 759 764
51. X Kang Y Kawakami M el-Gamil R Wang K Sakguchi JR Yannelli Identification of a tyrosinase epitope recognized by HLA-A24–restricted, tumor-infiltrating lymphocytes J Immunol 155 1995 1343 1348
52. VG Brichard J Herman A Van Pel C Wildmann B Gaugler T Wolfel A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes Eur J Immunol 26 1996 224 230
53. AL Cox J Skipper Y Chen RA Henderson TL Darrow J Shabanowitz Identification of a peptide recognized by five melanoma specific human cytotoxic T cell lines Science 264 1994 716 719
54. AB Bakker MW Schreurs G Tafazzul AJ de Boer Y Kawakami GJ Adema Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1–restricted anti-melanoma CTL line Int J Cancer 62 1995 97 102
55. Y Kawakami S Eliyahu C Jennings K Sakaguchi X Kang S Southwood Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression J Immunol 154 1995 3961 3968
56. AB Bakker MW Schreurs AJ de Boer Y Kawakami SA Rosenberg GJ Adema Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes J Exp Med 179 1994 1005 1009
57. Y Kawakami S Eliyahu CH Delgado PF Robbins K Sakaguchi E Appella Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection Proc Natl Acad Sci U S A 91 1994 6458 6462
58. JC Skipper DJ Kittlesen RC Hendrikson DD Deacon NL Harthun SN Wagner Shared epitopes for HLA-A3 restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100 J Immunol 157 1996 5027 5033
59. PG Coulie V Brichard A Van Pel T Wolfel J Schneider C Traversari A new gene encoding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas J Exp Med 180 1994 35 42
60. Y Kawakami S Eliyahu K Sakaguchi PF Robbins L Rivoltini JR Yannelli Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2–restricted tumor infiltrating lymphocytes J Exp Med 180 1994 347 352
61. C Castelli WJ Storkus MJ Maeurer DM Martin EC Huang BN Pramanik Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes J Exp Med 181 1995 363 368
62. AE Chang JD Geiger VK Sondak S Shu Adoptive cellular therapy of malignancy Arch Surg 128 1993 1281 1290
63. AR Miller WH McBride K Hunt JS Economou Cytokine-mediated gene therapy for cancer Ann Surg Oncol 1 1994 436 450
64. AE Chang VK Sondak DK Bishop BJ Nickoloff RC Mulligan JJ Mule Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene Human Gene Ther 7 1996 773 792
65. GJ Nabel D Gordon DK Bishop BJ Nickoloff Y Zhi-Yong A Atsushi Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes Proc Natl Acad Sci U S A 93 1996 15388 15393
66. K Nagy New database allows researchers to evaluate cancer care costs J Natl Cancer Inst 85 1993 351 353
67. M Weiss CL Loprinzi ET Creagan RJ Dalton P Novotny JR O’Fallon Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas JAMA 274 1995 1703 1705
68. N Basseres JJ Grob MA Richard X Thirion H Zarour C Noe Cost-effectiveness of surveillance of stage I melanoma: a retrospective appraisal based on a 10-year experience in a dermatology department in France Dermatology 191 1995 199 203
69. AC Buzaid AB Sandler S Mani AM Curtis WJ Poo JL Bolongnia Role of computed tomography in the staging of primary melanoma J Clin Oncol 11 1993 638 643
70. AC Buzaid L Tinaco MI Ross SS Legha RS Benjamin Role of computed tomography in the staging of patients with local-regional metastases of melanoma J Clin Oncol 13 1995 2104 2108
71. BW Kuvshinoff C Kurtz DG Coit Computed tomography in evaluation of patients with stage III melanoma Ann Surg Oncol 4 1997 252 258
72. TM Johnson DJ Fader AE Chang A Yahanda JWI Smith KR Hamlet Computed tomography in staging of patients with melanoma metastatic to the regional nodes Ann Surg Oncol 4 1997 396 402